Please login to the form below

Not currently logged in
Email:
Password:

Breo Ellipta

This page shows the latest Breo Ellipta news and features for those working in and with pharma, biotech and healthcare.

Sovaldi pushes Gilead to the top of US pharma list

Sovaldi pushes Gilead to the top of US pharma list

The London-based firm has also failed to increase market share for its next-gen versions of Advair - namely Breo, Ellipta and Anoro Ellipta - which had combined sales last year of

Latest news

  • China weighs heavy on GSK figures in Q3 China weighs heavy on GSK figures in Q3

    There were also launches for melanoma drugs Tafinlar (dabrafenib) and Mekinist (trametinib), Tivicay (dolutegravir) for HIV via GSK's ViiV joint venture with Pfizer and Shionogi, and new COPD therapy Breo ... Ellipta (fluticasone furoate and vilanterol).

  • GSK wins US approval for Seretide successor Breo Ellipta GSK wins US approval for Seretide successor Breo Ellipta

    GSK wins US approval for Seretide successor Breo Ellipta. FDA gives green light to COPD combination. ... The partners plan to launch Breo Ellipta in the US during the third quarter of this year.

  • GSK buoyed by FDA panel backing for Advair successor GSK buoyed by FDA panel backing for Advair successor

    Breo, delivered once-daily using a new Ellipta inhaler, is seen as a critical drug for GSK as it tries to defend its asthma and COPD franchise dominated by twice-daily ... Breo Ellipta (which will be sold as Relvar in Europe) is being positioned by GSK

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics